Novonesis (Novozymes) B (STU:NZM2)
€ 56.8 0.18 (0.32%) Market Cap: 26.55 Bil Enterprise Value: 28.28 Bil PE Ratio: 38.85 PB Ratio: 2.40 GF Score: 97/100

Q3 2019 Novozymes A/S Earnings Call Transcript

Oct 23, 2019 / 07:00AM GMT
Release Date Price: €43.04
Peder Holk Nielsen;S;President;CEO
Novozymes A

/-&

Good morning, and welcome to the Novozymes conference call. Today, we'll review our performance for the first 9 months of 2019 as well as our outlook and our current priorities. As we hosted the conference call on October 10 following the updated full year outlook, today's presentation will be shorter and should take no more than about 15 minutes. Afterwards, we'll be happy to take your questions.

My name is Peder Holk Nielsen, and I'm the CEO of Novozymes. I'm joined here today by the Executive Leadership Team and Investor Relations.

Before we jump into the subject matter, I would like to take this opportunity to properly welcome Lars Green to the Executive Leadership Team. He has held various financial positions at Novo Nordisk both in Denmark and abroad and has since 2017 been a member of the Novo Nordisk executive management team. Lars knows Novozymes very well as he has been on the Board and been the Chairman of the Audit Committee since 2014. I think he's the perfect match for us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot